New England Power Company

Zaiput Flow Technologies LLC, located in Waltham, MA, specializes in advanced phase separation and extraction technologies, providing innovative solutions for liquid-liquid and gas-liquid separation applications. Their product offerings include production scale separators, extraction platforms, and optimization services tailored to enhance liquid-liquid extraction and partition chromatography processes. With a focus on technological development, Zaiput serves various industries through its cutting-edge solutions in heterogeneous catalysis and pressure regulation. The company is committed to providing customer support and training resources while actively engaging in partnerships and collaborations worldwide. Generated from the website

New England Donor Services, located in Waltham, MA, is dedicated to promoting organ and tissue donation within the community. Through their various programs and partnerships, they aim to educate the public on the importance of donation and support donor families throughout the process. In addition to facilitating living donations and managing donor registries, New England Donor Services provides resources for medical professionals and partners, ensuring that those in need receive the necessary support and information related to organ donation. Their commitment to saving lives and honoring donors is reflected in their ongoing outreach and advocacy efforts. Generated from the website

Morphic Therapeutic Inc is a pioneering biopharmaceutical company based in Waltham, MA, specializing in the development of oral integrin medicines. Leveraging their extensive expertise in integrin biology, they aim to transform treatment paradigms for patients across multiple therapeutic areas, including autoimmune diseases, fibrosis diseases, and cancer. Their lead candidate, MORF-057, is a highly specific inhibitor of 4 7 currently in Phase 2 for inflammatory bowel disease (IBD). With a pipeline that encompasses both novel and highly validated targets, Morphic Therapeutic is committed to drugging integrins through small molecules to address unmet medical needs. They have also established a research partnership with Janssen to discover inhibitors of undisclosed integrin targets, expanding their knowledge of integrin biology into modalities beyond small molecules. Additionally, Morphic is actively developing small molecule inhibitors for the treatment of pulmonary arterial hypertension (PAH), solid tumors, and other indications, utilizing their MInT Platform to create therapeutically relevant compounds with enhanced attributes.Generated from the website